Infliximab for Treatment of Immune Checkpoint Inhibitor Colitis
Phase II Study of Infliximab for the Treatment of Immune Checkpoint Inhibitor Colitis
Sponsor: Dana-Farber Cancer Institute
A PHASE2 clinical study on Drug Toxicity and Drug-Induced Colitis, this trial is ongoing. The trial is conducted by Dana-Farber Cancer Institute and has accumulated 11 data snapshots since 2020. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
11 versions recorded-
Feb 2026 — Present [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Oct 2025 — Feb 2026 [monthly]
Recruiting PHASE2
-
Sep 2025 — Oct 2025 [monthly]
Recruiting PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE2
▶ Show 6 earlier versions
-
Apr 2024 — Jul 2024 [monthly]
Recruiting PHASE2
Status: Unknown Status → Recruiting
-
Nov 2023 — Apr 2024 [monthly]
Unknown Status PHASE2
Status: Recruiting → Unknown Status
-
Nov 2021 — Nov 2023 [monthly]
Recruiting PHASE2
-
Jan 2021 — Nov 2021 [monthly]
Recruiting PHASE2
-
Oct 2020 — Jan 2021 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Apr 2020 — Oct 2020 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Dana-Farber Cancer Institute
- Massachusetts General Hospital
For direct contact, visit the study record on ClinicalTrials.gov .